Interaction between the complement system and carbon nanotubes (CNTs) can modify their intended biomedical applications. Pristine and derivatised CNTs can activate complement primarily via the classical pathway which enhances uptake of CNTs and suppresses pro-inflammatory response by immune cells. Here, we report that the interaction of C1q, the classical pathway recognition molecule, with CNTs involves charge pattern and classical pathway activation that is partly inhibited by factor H, a complement regulator. C1q and its globular modules, but not factor H, enhanced uptake of CNTs by macrophages and modulated the pro-inflammatory immune response. Thus, soluble complement factors can interact differentially with CNTs and alter the immune response even without complement activation. Coating CNTs with recombinant C1q globular heads offers a novel way of controlling classical pathway activation in nanotherapeutics. Surprisingly, the globular heads also enhance clearance by phagocytes and down-regulate inflammation, suggesting unexpected complexity in receptor interaction.
A rapid recognition and clearance of nanoparticles including carbon nanotubes (CNTs) from the systemic circulation by the immune system can seriously undermine the intended application of nanoparticles as intravenous drug delivery platforms. 1 Therefore, understanding how nanoparticles interact with cellular and humoral immune components is essential for their strategic and specific in vivo use. [1] [2] [3] [4] [5] [6] The innate immune system plays a key role in the recognition and clearance of pathogens, altered-self, and synthetic particles including nanoparticles. 1, 3, [6] [7] [8] The complement system is one of the key innate immune mechanisms and is activated through three pathways. The classical pathway is initiated by C1q, a charge pattern recognition protein consisting of 18 chains (6A, 6B and 6C) each composed of an N-terminal collagen domain (cC1q) and a C-terminal globular head (gC1q) domain. These polypeptides assemble to form a structure of 6 heterotrimeric globular heads, linked together by the collagen regions. C1q most notably binds to IgG and IgM-bearing immune complexes through its gC1q domains, but can also bind charge clusters/ hydrophobic patches on self, non-self and altered-self targets. 9, 10 C1q binding to its targets activates proteases C1r and C1s, which are bound to the cC1q domain, and C1s activates C4 and C2 forming C4b2a (a C3 convertase) which activates C3, forming C3a and C3b, of which the latter can bind to the target surface. C3b and its breakdown products iC3b and C3d interact with C3 receptors on phagocytic cells. 10 C3b also binds to C4b2a, forming C4b2a3b, a protease that can bind and activate C5, and ultimately drives formation of C5b-9 (the membrane attack complex; MAC), which forms a channel in membranes, lysing cells. 10 In the lectin pathway, binding of MBL or ficolins to targets via vicinal-diols or acetyl-groups on sugars activates MASPs, leading to C4 and C2 activation. 10 In the alternative pathway, hydrolysis of a thiol-ester in C3 to form C3(H 2 O) results in formation of a complex with factor B, which is cleaved by factor D, to form C3(H 2 O)Bb (a homologue of C4b2a). C3(H2O)Bb activates C3, to form C3a and C3b, which can bind covalently to surfaces. Surface-bound C3b then interacts with factor B and factor D to yield C3 convertase (C3bBb). C3bBb, an unstable protease, can be stabilized by properdin to form C3bBbP. Factor H (FH) regulates the alternative pathway by binding to C3b, inhibiting interaction with factor B, and then factor I, a regulatory protease, cleaves C3b in the C3b-FH complex to form iC3b, a potent opsonin, which is unable to form C3bBb. [10] [11] [12] Like C1q, FH binds to targets mainly via interactions with charge clusters, and thus competes with C1q for binding to some targets, thereby also inhibiting classical pathway activation. 11, 13 Pristine and functionalized CNTs activate complement, mainly through the classical pathway, and to a minor extent through the alternative 3, 4, 6, 8, [14] [15] [16] [17] [18] and the lectin pathways. 4, 19, 20 Complement activation by CNTs offers an intriguing challenge since C3b-opsonized CNTs can be cleared via complement receptors on phagocytes 21 prior to reaching the targeted tissue for drug delivery. Complement by-products (C3a, C4a, and C5a) are potent anaphylatoxins, and can induce inflammation and hypersensitivity reactions. 3, 8, 10 MAC formation can potentially cause damage to cells and tissues in close vicinity of complement-activating nanoparticles. 6 Classical pathway-activating CNTs get internalized more efficiently by macrophages, leading to down-regulation of pro-inflammatory cytokines. 21 However, Au-Ni nanowires of similar dimensions activate complement very poorly, causing reduced phagocytosis and increased pro-inflammatory response by immune cells. 22 Complement deposition can potentially sequester CNTs away from PAMP-PRR engagement on immune cell surfaces, and dampen inflammation via up-regulation of anti-inflammatory IL-10. 22 Surface modifications of hydrophobic CNTs are essential to disperse them in aqueous media that can be achieved by covalent or non-covalent surface coating. Non-covalent adsorption of dispersants (proteins, polymers and nucleic acids) onto the CNT surface does not alter their structure. Covalent functionalization alters their walls by making small defects, commonly via oxidation, leading to carboxyl groups on the surface. 23 Here, we functionalized a type of pristine multi-walled CNT (MWNT), covalently by oxidation (Ox-MWNT), or non-covalently with carboxymethyl-cellulose (CMC-MWNT), each having carboxyl functional groups. Given that CNTs (pristine or functionalized) offer repetitive recognition patterns of polarity and hydrophobicity, we examined the nature of interaction of C1q, the first recognition subcomponent of the classical pathway, with Ox-MWNT and CMC-MWNT. We also included FH in the study, a competitive inhibitor of C1q for certain ligands, which can act as a regulator of classical as well as alternative pathway. 24 Both C1q and FH, which can be locally synthesised during immune cell activation, can have functions without involving complement activation. 25 Here, we show differential interaction of C1q and FH with CNTs, which can impact upon complement activation, phagocytosis, and immune response.
Methods and materials

Dispersion of MWNTs by non-covalent and covalent functionalization
MWNTs were purchased from Arry Nano, Germany with an outer diameter of 10-20 nm and a length of 5-20 μm. Non-covalent functionalization was achieved by 2 min sonication in PBS in 2:1 mass ratio with CMC (Sigma), followed by centrifugation at 8000g to remove clusters, washing in PBS, and filtration of excess CMC using a 0.2 μm filter (Whatman). For covalent functionalization, a modified procedure described by Li et al 23 was used. 100 mg of pristine MWNTs was added to a 50 ml mixture of H 2 SO 4 (10 M) and HNO 3 (10 M) in 3:1 ratio, sonicated in a water-bath (RT for 1 h), and then probe-sonicated for 30 min (50% ON, 50% OFF) on ice, in order to exfoliate the MWNTs and homogenize the dispersion. After being refluxed at 120°C for 48 h, the resulting mixture of Ox-MWNTs, after being cooled down and diluted with distilled water, was centrifuged at 11,000g for 30 min. Water was added to the pellets to re-suspend Ox-MWNTs and then centrifuged three times. The amorphous carbon due to the partial oxidation of the outer structure was removed by stirring the Ox-MWNTs in 10 mM NaOH overnight. 26 The dispersion was then filtered through a 0.1 μm filter, followed by extensive washing in water in order to remove NaOH. Ox-MWNTs were dialyzed against distilled water and washed in PBS.
Purification of C1q and factor H from human plasma
C1q and FH were purified from human plasma as described previously. 13 Recombinant human C1q globular head modules (ghA, ghB and ghC) and substitution mutants Complement consumption and hemolytic assays for the classical pathway A complement consumption assay was performed as described earlier 6 to examine modulation of the classical pathway activation by protein-coated CNTs. Samples of coated and uncoated CMC-MWNT and Ox-MWNT (100 μg/ml in affinity buffer) were incubated with occasional shaking at 37°C for 1 h with an equal volume of human serum 1:1 diluted in dextrose gelatin veronal buffer (DGVB ++ ; 2.5 mM sodium barbital, 71 mM NaCl, 0.15 mM CaCl 2 , 0.5 mM MgCl 2 , 2.5% w/v glucose, 0.1% w/v gelatin, pH7.4). This was followed by centrifugation (13,000g, 10 min), and the collected supernatants were tested for their complement activity by measuring the capacity to lyse antibody-sensitized sheep erythrocytes (EA; Ref. 6 ). 100 μl of EA cells (1 × 10 8 cells/ml in DGVB ++ ) were added to serial dilutions (100 μl) of each supernatant in DGVB ++ and incubated for 1 h at 37°C. Following centrifugation (5000 rpm, 5 min), 100 μl of the supernatant was collected and released hemoglobin was measured at 405 nm. Total hemolysis (100%) was measured by lysing EA with water. Background spontaneous hemolysis (0%) was determined by incubating EA with buffer (DGVB ++ ) only. Serum diluted identically but without CNTs was used as positive control.
Biotinylation of CNTs
CMC-MWNT and Ox-MWNT were dialyzed into 0.1 M MES buffer, pH 5 and their concentration adjusted to 0.2 mg/ml. Pentylamine biotin (Pierce; 2 mg) was added to 2 ml of CMC-MWNT or Ox-MWNT and 20 μl of a 20 mg/ml solution of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, Sigma) was added and incubated at RT for 2 h with stirring, and then biotinylation was stopped by adding 100 μl of 0.1 M ethanolamine pH 8.2 (Sigma). The resulting biotin-CMC-MWNT and biotin-Ox-MWNT were dialyzed against PBS in order to remove residual reactants and MES.
Phagocytosis assay
U937 cells (a monocytic cell line derived from histiocytic lymphoma) were cultured in complete RPMI-1640 (GIBCO) containing 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 1 mM sodium pyruvate (all from Sigma), and passaged and washed in AIM-V Albumax serum free medium (GIBCO) before use. In each well of a 24 well plate, 5 × 10 5 cells were seeded in AIM-V AlbuMAX serum free medium with supplements but no FCS.
Twenty micrograms of biotin-CMC-CNT or biotin-Ox-MWNTs coated with C1q, factor H, ghA, ghB or ghC was added to each well and incubated for 6 h. Cells were harvested and washed 5 times in PBS (centrifugation at 300g) and stored at − 80°C until further use. All experiments were performed in duplicate.
For quantification of phagocytosis, 21 25 μl lysis buffer (10 mM HEPES, 20 mM NaCl, 0.5 mM EDTA, 1% w/v Triton X 100) was added to the cell pellets. After cell lysis, 25 μl of 0.1 mg/ml horse IgG (MRC ICU, Oxford) in PBS was added (as a blocking agent) to the dispersion. Microtitre wells (NUNC, polysorb) were coated with 100 μl Avidin (Pierce) at 50 μg/ml in 0.1 M Na 2 CO 3 , pH 9.0 for 1 h at RT, followed by blocking with 1 mg/ml horse IgG in PBS for 1 h at RT. Next, 50 μl of a solution or cell lysate containing biotin-CMC-MWNT or biotin-Ox-MWNT and 50 μl of 0.1 mg/ml horse IgG was incubated for 1 h in each well. The plate was washed 7 times with 0.1 mg/ml horse IgG in PBS to remove excess CNTs and then incubated with 1:2000 Streptavidin-HRP (Sigma) for 1 h at RT. TMB (Biolegend, UK) was used as a substrate for HRP and the yellow product was read at 450 nm.
Isolation of human macrophages and fluorescence microscopy
CMC-MWNTs were suspended in 0.1 M MES, pH 5 and labeled with AlexaFluor488-cadaverine (Invitrogen) for 2 h at RT in a 2:1 mass ratio in the presence of 1 mM EDC. Labeled CMC-MWCNTs were recovered by centrifugation (10,000g, 10 min) and washed 3 times with PBS to remove unincorporated label. Purified proteins were incubated overnight at a 2:1 mass ratio with AlexaFluor488-cadaverine labeled CMC-MWNT in affinity buffer at 4°C with agitation. Excess protein was removed by washing twice with PBS. Treated AlexaFluor488-cadaverine labeled CMC-MWNTs were recovered by centrifugation and dispersed in PBS in a water bath sonicator.
The uptake of protein-treated and untreated, fluorescently-labeled CMC-MWNT was examined using monocyte-derived human macrophages as described in Ref. 22 . Human PBMCs (1 × 10 6 ) were seeded on 13 mm diameter cover slips and incubated for 14 days at 37°C, 5% CO 2 in a humidified atmosphere. Mature macrophages were exposed to 4 μg/ml protein-treated or untreated AlexaFluor488-cadaverine labeled CMC-MWCNTs in 500 μl of serum-free medium for 3 h. Cells were washed twice with PBS, fixed with 4% formaldehyde for 10 min, washed twice, and processed for immunofluorescence. The coverslips were stained for 30 min with 1.6 μM Hoechst 33342 and 2 μg/ml AlexaFluor546-conjugated wheat germ agglutinin (Invitrogen). Cells were then washed twice, mounted using Citifluor anti-fade (Citifluor, UK) and observed with a Zeiss 780 confocal microscope with 40× oil-lens using ZEN software (Zeiss, UK).
Quantitative PCR analysis for cytokine mRNA expression
In a 24-well plate, 10 μg of protein-coated CMC-MWNTs or Ox-MWNTs in 500 μl of PBS were added to each well containing 5 × 10 5 U937 cells in AIM-V Albumax serum-free medium and incubated for 15, 30, 45, 60, 120 or 360 min inside a 5% CO 2 -95% air incubator at 37°C (PBS only for 30 min as control). Cells were harvested and spun down (3000g, 5 min) and stored at − 80°C. Total RNA was extracted from frozen cell pellets using the GenElute Mammalian Total RNA Purification Kit (Sigma-Aldrich). Following DNase treatment, samples were heated at 70°C for 10 min to inactivate DNase and RNase, and then chilled on ice. The amount of total RNA was determined at 260 nm using the NanoDrop 2000/2000c spectrophotometer (Thermo-Fisher Scientific), and the purity using the ratio of absorbance at 260/280 nm ratio. The cDNA was synthesized using High Capacity RNA to cDNA Kit (Applied Biosystems) using 2 μg of total RNA extract.
Primer sequences, designed and analyzed for specificity via http:// blast.ncbi.nlm.nih.gov/Blast.cgi), included: 18S forward (5′-ATGGCCGTTCTTAGTTGGTG-3′), 18S reverse (5′-CGCTGAGCCAGTCAGTGTAG-3′); IL-1β forward (5′-GGA CAAGCTGAGGAAGATGC-3′), IL-1β reverse (5′-TCGTTATCC CATGTGTCGAA-3′); IL-6 forward (5′-GAAAGCAGCAAA GAGGCACT-3′), IL-6 reverse (5′-TTTCACCAGGC AAGTCTCCT-3′); IL-10 forward (5′-TTACCTGGAGGAGGTG ATGC-3′), IL-10 reverse (5′-GGCCTTGCTCTTGTTTTCAC-3′); IL-12 forward (5′-AACTTGCAGCTGAAGCCATT-3′), IL-12 reverse (5′-GACCTGAACGCAGAATGTCA-3′); TGF-β forward (5′-GTACCTGAACCCGTGTTGCT-3′), TGF-β reverse (5′-G TATCGCCAGGAATTGTTGC-3′); TNF-α forward (5′-AGCCC ATGTTGTAGCAAACC-3′), TNF-α reverse (5′-TGAGGTACA GGCCCTCTGAT-3′); NF-κB forward (5′-GTATTTCAACCACA GATGGCACT-3′), NF-κB reverse (5′-AACCTTTGCTGGTCCCA CAT-3′); NLRP3 forward (5′-GCCATTCCCTGACCAGACTC-3′) and NLRP3 reverse (5′-GCAGGTAAAGGTGCGTGAGA-3′).
The qPCR reaction (10 μl) consisted of 5 μl Power SYBR Green MasterMix (ABI), 75 nM of forward and reverse primer and 500 ng template cDNA. PCR was performed using a Step One Plus Real-Time PCR System (ABI). After initiation steps of 2 min at 50°C and 10 min at 95°C, the template was amplified for 40 cycles (15 s at 95°C, 1 min at 60°C). Samples were normalized using the expression of human 18S rRNA. Data were analyzed using the Step One software v2.3. Ct (cycle threshold) values for each cytokine target gene were calculated. Relative expression of each cytokine target gene was calculated using the Relative Quantification (RQ) value, using the equation: RQ = 2 − ΔΔCt for each cytokine target gene, and comparing relative expression with that of the 18S rRNA constitutive gene product. Assays were conducted in triplicate.
Multiplex cytokine array analysis
Cytokines (IL-6, IL-8, IL-10, IL12p40, IL12p70, IL-23, IL-27, IL-1α and IL-1β) and chemokines/growth factors (MIG, I-TAC, MCP-1, G-CSF and M-CSF) concentrations in the supernatants of U937 cells were measured by MagPix Milliplex kit (EMD Millipore). Cells were incubated with protein-coated and uncoated CMC-MWNTs and Ox-MWNTs as above for 48 h, and then spun down at 300g and supernatants were stored at − 80°C until use. Briefly, 25 μl of assay buffer was added to each well of a 96-well plate, followed by addition of 25 μl of standard, controls or supernatants of (CNT treated) cells, to appropriate wells. Twenty-five microliters of magnetic beads coupled to analytes was added in each well, and incubated for 18 h at 4°C. After washing the plate with assay buffer, 25 μl of detection antibodies was incubated with the beads for 1 h at RT. Twenty-five microliters of streptavidin-phycoerythrin was then added and incubated for 30′. Following a washing step, 150 μl of sheath fluid (BD Biosciences) was added to each well and the plate was read using the Luminex Magpix instrument.
Results
Oxidation, coating and dispersion of CNTs
Pristine MWNTs of 5-20 μm length and a diameter of 10-20 nm (Figure 1, A) were well-dispersed by non-covalent coating with CMC; being stable over months, no sedimentation/ clustering is seen (by light microscopy; not shown). Oxidation was achieved by treatment with concentrated acids (Figure 1, D) . Defects seen on the surface of the Ox-MWNTs via TEM imaging (Figure 1, B) were absent on pristine MWNTs ( Figure 1, A) ; CNTs were significantly shortened (length 100-500 nm; Figure 1, C) . NaOH treatment removed all amorphous carbon from the CNT surface. Ox-MWNTs were stable over months even at N 1 mg/ml without clustering/sedimentation. Figure  1, A and B 
Binding of wild type and substitution mutants of individual C1q globular domains to CNTs suggests a charge-charge interaction
Coating of CNTs with innate immune humoral factors and effect on classical pathway complement activation
When C1q-coated Ox-MWNT and CMC-MWNT were examined for the classical pathway activation, complement consumption was inhibited by 40% for Ox-MWNTs but there was no inhibition for CMC-MWNT (Figure 3) , suggesting differential orientation of C1q on the CNT surface. CNT-bound C1q must either sequester C1r and C1s from C1 in the serum, or be replaced by C1. Since ghA, ghB and ghC do not apparently dissociate (see below), the interaction of C1q with Ox-MWNT may be at least partially in a conformation which does not allow capture of C1r and C1s. Coating with ghA, ghB and ghC also considerably inhibits the classical pathway activation by serum. 21 CNTs, when pre-coated with FH (Figure 3 ), were also able to consume 40% less complement than the uncoated CNTs. This indicates that FH is inhibiting binding of C1 (C1q) from serum, possibly recognizing motifs that are overlapping/ identical to those recognized by C1q, consistent with the emerging evidence that for certain C1q ligands, such as anionic phospholipids, lipid A, apoptotic cells and β amyloid peptide 1-42, FH can be an inhibitor of the classical pathway. 11, 13, 24, 30 Effect of CNT coating with C1q, ghA, ghB, ghC and factor H on phagocytosis by U937 cell line and human macrophages For CMC-MWNT, phagocytosis was increased by C1q (3.5-fold), ghA (4-fold), and ghC (7-fold) (Figure 4, A) . For Ox-MWNT, no significant effect was seen for any of the globular head modules, but phagocytosis was slightly higher with C1q (1.3 fold). For FH, a 2.6 fold reduction of uptake of Ox-MWNT was seen, but FH did not enhance or diminish uptake of CMC-MWNT. The enhancement of CMC-MWNT uptake by individual gC1q modules is novel and curious. Confocal microscopy using human macrophages confirmed that C1q and the recombinant gC1q modules, but not FH, enhanced uptake of CMC-MWNTs (Figure 4, B) . Single confocal sections with higher magnification of the membrane revealed qualitative localization of CNTs inside the cells except in the case of FH (Figure 4, C) .
Cytokine and transcription factor mRNA expression by U937 cells treated with protein-coated Ox-MWNTs and CMC-MWNTs IL-10 mRNA expression by U937 cells was dramatically up-regulated (300-fold by 6 h) by Ox-MWNT from 15 min onwards (Supplementary Figure 2) ; for CMC-MWNT, the up-regulation was seen only after 2 h. For Ox-MWNT, pre-coating with C1q and ghC dampened the IL-10 expression compared to uncoated Ox-MWNTs. For CMC-MWNTs, all proteins except FH had an inhibitory effect on IL-10, ghC being the most pronounced. IL-12 transcription was considerably up-regulated for Ox-MWNTs by ghA, ghB and ghC, but not as much as by C1q and FH. IL-12 expression was down-regulated by CMC-MWNT on its own, and further dampened by FH. For Ox-MWNTs, TGF-β was down-regulated by C1q, but overall up-regulated by FH, ghB and ghC, suggesting an immunosuppressive effect. However, for CMC-MWNT, C1q and gC1q modules up-regulated TGF-β transcripts while FH down-regulated, suggesting patterndependent modulation of anti-inflammatory response. IL-1β was up-regulated for all Ox-MWNT; for CMC-MWNT, there was initially a down-regulation of IL-1β, but it increased at 2 h and 3 h, consistent with NLRP3 expression. For IL-6, CMC-CNT (uncoated) caused a consistently moderate down-regulation, which was generally reversed by coating with C1q, FH, ghA, ghB and ghC. TNF-α was up-regulated by Ox-MWNTs; most proteins induced up-regulation at various time points, consistent with NF-κB expression profile (Supplementary Figure 2) .
Modulatory effects of protein-coated CNTs on cytokine/chemokine secretion by U937 cells
Cytokine array analysis using supernatants at 48 h from experiments as in Supplementary Figure 2 revealed that FH suppressed MCP-1, IL-8 and TNF-α (FH more pronounced for Ox-MWNT), IL-10, IL-1α and IL-1β. C1q, as opposed to FH, enhanced TNF-β, IL-1β, IL-10 and G-CSF secretion. All three globular modules suppressed IL-8 and G-CSF, while TNF-α was suppressed by ghB and ghC. IL-10 secretion was slightly enhanced whereas ghB considerably suppressed IL-1α and IL-1β for CMC-MWNT. They also enhanced G-CSF production whereas only ghA was able to enhance IL-12 secretion ( Figure 5 ).
Discussion
Due to a range of structural and functional attributes, CNTs have wide ranging applications in translational medicine. [31] [32] [33] [34] [35] Their systemic administration for vaccination and drug delivery 31, 34, 36 inevitably brings them in contact with complement. Any surface that offers a molecular pattern as a signature of non-self and altered-self is amenable to complement recognition and activation. Complement deposition on CNTs, mainly via the classical pathway, 3, 6, 17, 21 enhances their uptake by complement receptor bearing APCs such as macrophages and B cells and down-regulates pro-inflammatory cytokines 21 via up-regulation of IL-10. 22 Curiously, Au-Ni nanowires, 22, 37 being poor complement activators, are potent inducers of pro-inflammatory response following serum treatment, suggesting that coating with other serum proteins in the absence of complement deposition can have deleterious consequences. 22 This brought the focus of this study on the nature of the interaction between C1q 9 and CNTs. All three recombinant globular head modules (ghA, ghB, ghC) bind onto the surface indicating the binding of C1q onto CNTs is likely through charge pattern recognition, which would enable binding of C1r and C1s via C1q for further complement activation. Coating the globular heads lead to effective inhibition of complement activation. 21 We used single residue substitute mutations of ghA, ghB and ghC in order to identify gC1q residues involved in the CNT-C1q interaction. These residues were selected for substitution mutation because of being hypervariable within the 3-D structure of the gC1q domain and their central/subsidiary involvement in interaction with known C1q ligands. [27] [28] [29] 38 We also examined the effects of CNT coating by C1q, ghA, ghB, ghC, and FH (as a potential down-regulator of the classical pathway) on phagocytosis and cytokine expression by macrophages. Salvador-Morales et al 8 have shown that FH reduces complement activation by CNTs through the alternative pathway. For a number of C1q ligands, FH acts an inhibitor of C1q, and thus dampens the classical pathway. 11, 13, 24, 30 C1q and FH can be locally synthesized in tissues, and thus bind to CNTs and alter their interaction with immune cells without involving complement activation.
C1q is a versatile pattern recognition innate immune molecule that recognizes an array of self, non-self and altered-self ligands. The broad-spectrum ligand-binding potential of C1q, and its subsequent effect on biological processes, is facilitated by the modular organisation of the heterotrimeric gC1q domain (where each module can have independence of structure and function), its ability to change its conformation in a very subtle way, and the manner in which this ancient molecule has evolved. 9, [38] [39] [40] The versatility and variability of C1q-ligand interaction are due to differences in electrostatic surface potentials of the different gC1q modules. 41 Substitution mutants used here were designed based on structure-function studies and ConSurf 42 where the most variable residues in the C1q family were considered most likely to be central to C1q-ligand interaction. Thus, Arg B114 and Arg B129 , known to be important for C1q-IgG interaction 27 did not seem crucial for CNTs. Interestingly, an increase of binding was found for substitution of the Arg C156 to Glu. These results appear to suggest involvement of side chains and hydrophobic patches within the gC1q domain in their interaction with CNTs. Binding of macromolecules on CNTs is not fully explored, but may involve charge transfer and hydrophobic interaction. 43, 44 Thus, molecular patterns offered by CNTs are likely to act as a nucleation centre for an ordered binding of C1q and FH. Here, residues within the gC1q domain that are peripheral/subsidiary to C1q binding with its known natural ligands appeared to be involved in C1q-CNT interaction. These molecular patterns may impact upon the level of C1q binding to CNTs, their clearance by phagocytic cells, and cellular toxicity.
Oxidized CNTs are in general considered less toxic than pristine CNTs. [45] [46] [47] [48] [49] [50] [51] These effects, and few disagreements, are due to reduction of impurities (catalyst) in the samples, a decrease in length of CNTs, an increase of functional groups, and higher dispersability leading to higher bioavailability. 52, 53 Bio-persistence is an important parameter for nanoparticle in vivo toxicity. In contrast to pristine CNTs, highly carboxylated CNTs were shown to be rapidly (within 3 h) cleared out of the systematic circulation through the renal excretion route. 48 Possible enzymatic degradation of CNTs with HRP 49, 54 and myeloperoxidase (expressed in neutrophils) 55 can thus be avoided since CNT oxidation reduces the time required for degradation. 49, 56 Thus, coating and downstream processing of CNTs can generate new molecular signatures that can be recognized by complement proteins including C1q.
The dissection of C1q interaction with CNTs is insightful given that C1q is capable of binding charge clusters, polar regions, or small hydrophobic patches. 38 Since CNTs offer repetitive patterns of polarity and hydrophobicity, C1q is well suited to bind them, activate the classical pathway, and also enhance their phagocytic uptake directly, even without further complement deposition. Here, we report that coating CNTs with recombinant globular heads can inhibit the classical pathway activation, enhance uptake of CNTs by phagocytic cells, and at the same time down-regulate pro-inflammatory cytokine response by macrophages: a very novel and surprising result since these molecules lack the collagen region of human C1q, which is generally thought to be implicated in binding to receptors involved in phagocytosis. However, there is at least one putative receptor, gC1qR which recognizes globular heads. 25 Thus, the mechanism of enhancement of CNT uptake by globular heads of C1q needs to be examined in future studies. We report a novel method of inhibition of nanoparticle-mediated activation of the classical pathway and subsequent handling by phagocytic cells through an anti-inflammatory route. In view of planned trials using CNTs coated with therapeutic antibodies 35, [57] [58] [59] [60] which are likely to offer an array of closely spaced Fc regions for C1q to bind, the study offers an opportunity to modify drug vehicles.
